Somatostatin Analogs Market Size & Share 2025 - 2034

Somatostatin Analogs Market Size

The global somatostatin analogs market size was estimated at USD 7.2 billion in 2024. The market is expected to grow from USD 7.6 billion in 2025 to USD 14.3 billion in 2034, at a CAGR of 7.2% during the forecast period. The rising incidence of disorders related to hormone overproduction, such as acromegaly and neuroendocrine tumors (NETs) coupled with increasing awareness of somatostatin analogs, increases the adoption rate of these drugs that contribute to market growth.

The global incidence of acromegaly is estimated at 3 to 4 cases per million people annually, whereas, the global prevalence of neuroendocrine tumors is increasing, with an estimated 35,000 new cases in the U.S. annually. Thus, with the growing awareness of diseases such as acromegaly and NETs, more patients are being diagnosed early. This results in higher treatment rates and increased use of somatostatin analogs (SSAs), thereby boosting market growth.
 

Furthermore, the market is bolstered by ongoing research and development activities for the development of more effective formulations and delivery systems such as long-acting injections that enhance the convenience and effectiveness of SSA treatments, encouraging wider adoption. For example, in March 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and extra-pancreatic NET (epNET).
 

Additionally, as the demand for personalized treatments become more common, patients with conditions such as acromegaly and NETs are increasingly receiving SSAs tailored to their specific needs, thereby contributing to market growth. For example, according to a report, personalized medicine approaches in oncology are expected to grow at a CAGR of over 10%, which is expected to positively impact SSA utilization. In addition, the continuous approvals of somatostatin analogs by regulatory bodies such as the U.S. Food and Drug Administration (FDA) for new indications and formulations have boosted the drug’s usage. This has resulted in a broader application for treating various types of disease, which drives market growth.
 

Somatostatin analogs are medications that help regulate excessive hormone production in the body. Certain neuroendocrine tumors (NETs) produce high levels of hormones, leading to a condition known as carcinoid syndrome. Somatostatin analogs serve as a potential treatment for individuals affected by this syndrome. These synthetic versions of somatostatin have an extended half-life, making them more effective. Currently, regulatory authorities have approved three somatostatin analogs: lanreotide and octreotide, classified as first-generation SSAs, and pasireotide, which belongs to the second generation.
 

Somatostatin Analogs Market Trends

The increasing prevalence of hormone-related disorders, with ongoing clinical trials and product development by pharmaceutical companies is the significant driver of the market.
 

• Pharmaceutical companies are investing heavily in research and development activities to develop novel somatostatin analogs with improved efficacy and safety. For instance, in March 2022 Ipsen announced investment in a new state-of-the-art electronic autoinjector for somatuline autogel/somatuline depot (lanreotide) to improve the injection administration experience for patients. The new device will be made in collaboration with Phillips-Medi size.
   
• These advancements are expected to increase the adoption rate and market potential, which will boost market growth.
   
• Moreover, the increasing prevalence of acromegaly and Cushing’s syndrome raises the demand for somatostatin analogs that helps in suppressing the growth hormone secretion, making them the primary treatment for acromegaly and related disorders.
   
• Additionally, the increasing investment in rare disease treatment by government and private organizations due to rising healthcare expenditure contributes to the expansion of SSA market. For example, as per the report published by the World Economic Forum, it has been estimated that the global healthcare expenditure is projected to reach USD 10 trillion by 2026. Out of which the U.S. alone spends over USD 800 billion annually on rare diseases, benefiting SSA treatments.
   
• Also, the favorable reimbursement policies for SSAs in key market region such as U.S., Europe and Japan are making treatment more accessible. The Orphan Drug Act in the U.S. provides incentives for developing treatments for rare diseases such as NETs and acromegaly, further driving investment in SSAs.
   
• Lastly, the rapidly growing geriatric population increases the risk of developing neuroendocrine tumors in geriatric population. For example, as per the report published by United Nations, the number of people aged 65+ is projected to reach 1.5 billion by 2050, increasing demand for SSA treatments, thereby contributing market growth.
   

Somatostatin Analogs Market Analysis

Based on type, the global market is divided into octreotide, lanreotide and pasireotide. The lanreotide segment dominated the market and was valued at USD 3.9 billion in 2024. The lanreotide segment is expected to reach from USD 3.5 billion in 2022, to USD 3.7 billion in 2023
 

• Lanreotide is primarily used for neuroendocrine tumors (NET) treatment, especially carcinoid tumors and pituitary adenomas. The rise in the number of patients diagnosed with NETs has directly contributed to the increased use of lanreotide.
   
• Moreover, lanreotide is available in long-acting formulations that allow for less frequent dosing compared to other somatostatin analogs. This has enhanced patient compliance and preference for lanreotide.
   
• Additionally, the ongoing research and development activities to expand the indications for lanreotide further drives the growth of the market. In addition, regulatory bodies such as U.S. FDA, EMA and others are providing increasing support for the expansion of lanreotide’ s therapeutic indications, which could further boost its market presence.
   
• Further, the increasing adoption of lanreotide in emerging markets is due to better healthcare infrastructure, improved access to drugs, and rising awareness of rare diseases. This growth is particularly seen in regions such as Asia-Pacific, including countries such as China and India, that has witnessed a surge in demand for somatostatin analogs.

Learn more about the key segments shaping this market

Download Free PDF

Based on indication, the global somatostatin analogs market is categorized into neuroendocrine tumors (NETs), acromegaly, and other indications. The neuroendocrine tumors (NETs) segment accounted for the highest market share of 46.8% in 2024.
 

• The increasing advancement in diagnostic techniques leads to the diagnosis of a greater number of neuroendocrine tumors (NETs). Thus, as awareness and detection techniques improve, the number of diagnosed cases of NETs is expected to increase, which increases the demand of somatostatin analogs thereby supporting the market growth.
   
• Moreover, there is a growing preference for targeted therapies in oncology, which has helped increase the adoption of somatostatin analogs in NET treatment. These therapies offer specificity with fewer side effects compared to traditional chemotherapy, that contributes to market growth.
   
• Furthermore, ongoing research and clinical trials focused on enhancing the effectiveness of somatostatin analogs for NETs are likely to expand market growth.
   
• Additionally, many pharmaceutical companies are investing in innovative formulations and combination therapies to improve outcomes for NET patients, thereby spur market growth.
   

Based on route of administration, the global somatostatin analogs market is categorized into oral and parenteral. The parenteral segment accounted for the highest market share in 2024 and is expected to grow with a CAGR of 7.1% during the analysis period.
 

• Parenteral methods of drug delivery, such as subcutaneous (SC) or intramuscular (IM) injections, allow somatostatin analogs to reach therapeutic levels in the bloodstream almost immediately. This is important for conditions like neuroendocrine tumors (NETs) and acromegaly where prompt and prolonged drug action is essential.
   
• On the other hand, patients with chronic diseases that need long-term treatment prefer subcutaneous routes of administration. This increases the market potential for somatostatin analogs.
   
• This route of administration bypasses the first-pass liver metabolism, which makes many drugs inactive when taken by mouth. As a result, more of the drug reaches the blood circulation, increasing its strength. This is particularly important for octreotide and lanreotide.
   
• Moreover, the progression of auto-injectors and pre-filled syringes has enhanced the convenience of parenteral routes which is associated with higher patient compliance. These advancements simplify self-administration, ensuring that patients receive the appropriate dose without professional healthcare assistance, and thereby driving market expansion.
   
• Further, increasing research and development activities in parenteral drug delivery systems has resulted in the creation of long-acting release (LAR) formulations that are aimed at reducing injection frequency. As an illustration, in December 2023, Camurus published a statement announcing that they had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oclaiz (CAM2029) - a monthly subcutaneous (SC) depot octreotide designed to treat acromegaly.
   
• Lastly, the reduction in the burdens associated with frequent dosing leads to improved patient satisfaction and adherence towards treatment which in turn improves their quality of life and also drives the evolution of the market.
   

Based on end use, the global somatostatin analogs market is categorized into hospitals, specialty clinics, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 9 billion by 2034.
 

• The advancement in treatment protocols and hospital adoption of somatostatin analogs, especially for NETs and acromegaly treatment to control hormone secretion and reduce tumor size makes them a valuable treatment option in hospital settings, thereby contributing to market growth.
   
• The higher spending on healthcare in both developed and developing regions helps the growth of hospitals and other specialized services, including those that use somatostatin analogs.
   
• Patients show increasing preference to receive injectable medications in clinical or hospital settings due to the availability of professional administration. Since somatostatin analogs need routine administration, hospitals are best suited for managing these treatments.

North America somatostatin analogs market held the largest market share of 46.5% in 2024 in the global market, and it is anticipated to expand at a 7% CAGR over the forecast period.
 

In 2024, the U.S. held a significant position in the North America market and was valued at USD 3 billion.
 

• Somatuline depot (lanreotide), Signifor (pasireotide), and several other SSA formulations have received approval from the U.S. Food and Drug Administration (FDA) for multiple somatostatin analogs, which expands their market scope.
   
• The increased availability of advanced diagnostic imaging technologies like PET and CT scans, along with more public awareness campaigns in the U.S., helps detect NETs and acromegaly conditions earlier. This has increased the number of people eligible for somatostatin analog therapies, driving market growth.
   
• Furthermore, the coverage provided by Medicare and private insurers in the U.S. supports the use of somatostatin analog-based treatments, aiding in the provision of sophisticated therapies to a greater portion of the population. The growth of insurance policies that support treatment of uncommon conditions accelerates market development.
   
• Moreover, the effect of the Affordable Care Act (ACA) alongside other healthcare reforms provides advanced healthcare facilities and services to a greater number of Americans, including the treatment of rare diseases. This has improved the accessibility of treatment for conditions that require somatostatin analogs, helping to stimulate market growth.
   

Germany somatostatin analogs shows strong growth potential in the Europe somatostatin analogs market.
 

• Germany has a large population of patients with chronic endocrine disorders such as acromegaly and neuroendocrine tumors (NETs). Long-term therapy with somatostatin analogs is required for these conditions.The German Society for Endocrinology estimates that approximately 5,000 to 6,000 people are living with acromegaly in Germany, with about 60 to 70 new cases being diagnosed each year.
   
• The availability of more advanced diagnostic technologies, along with the increasing prevalence of hormone-related disorders, raises the demand for somatostatin analogs, which contributes to the market growth.
   
• Patient advocacy groups such as the German Society for Endocrinology and Neuroendocrine Tumor Society NETS are also working toward better awareness and treatment options for these diseases, which in turn increases the demand for somatostatin analogs.
   
• The growing application of somatostatin analogs in the treatment of NETs and acromegaly remains one of the contributing factors for growth. The increasing demand for injectable somatostatin analogs used to treat neuroendocrine tumors has been especially high, considering that NETs is prevalent in Germany, which increases the market size.
   

The somatostatin analogs market in Asia Pacific is estimated to grow at a CAGR of 7.5% over the next few years.
 

• NETs and acromegaly are emerging endocrine disorders in the region. The increasing awareness and improved diagnostic capabilities are helping to refine the detection rates. For example, there is a sharp increase in NET diagnoses in India, Japan, and South Korea, which makes the use of somatostatin analogs necessary.
   
• Furthermore, the Asia Pacific region has an aging population that is more vulnerable to many diseases, including hormonal disorders and tumors. These conditions are expected to increase the use of somatostatin analogs in the region, which will lead to growth in the market.
   

China somatostatin analogs market is poised to witness high growth in the Asia Pacific market over the analysis period
 

• Improved medical imaging and diagnostic techniques are leading to better recognition and diagnosis of NETs in China. The increase in cancer patients in China is contributing to the growing NET diagnoses globally.
   
• China's healthcare system continues to improve. First-tier cities in China, such as Beijing, Shanghai, and Guangzhou, have their own top-tier hospitals that are equipped with advanced technology for the diagnosis and treatment of NETs and acromegaly. This increases the SSA supply and demand in these metropolitan cities.
   
• Moreover, there is a variety of somatostatin analogs available in China due to interest from multinational Chinese pharmaceutical companies. Additionally, the Chinese government's increasing focus on domestic production of advanced biologics, including somatostatin analogs, is reducing the reliance on foreign products.
   

Brazil's somatostatin analogs market is projected to witness significant growth in the Latin America market in coming years.
 

• Brazil has been improving its healthcare system through public and private sector investments, which enhance healthcare access. Hospitals and healthcare centers are increasingly offering specialized treatments, including those for NETs and acromegaly, which drives the demand for somatostatin analogs.
   
• The Brazilian Sistema Unico de Saude (SUS), the national healthcare system, often provides subsidies or free access to treatments for certain diseases. Since somatostatin analogs are part of the treatment for diseases such as acromegaly and NETs, this drives the demand, especially in low-income populations.
   
• The increasing R&D investment in Brazil, along with several research institutions that focus on endocrinology and oncology, is leading to the introduction of more advanced and effective treatment options, including somatostatin analogs.
   

Saudi Arabia is anticipated to grow in the Middle East and African somatostatin analogs market.
 

• Saudi Arabia has been investing heavily in its healthcare sector to enhance medical facilities and services. These improvements help provide better diagnosis and treatment options for patients, leading to a higher demand for specialized medications such as somatostatin analogs.
   
• The Saudi government has implemented policies to improve healthcare access and affordability. These initiatives support the availability and use of advanced treatments, including somatostatin analogs, which helps drive market growth.
   
• The increasing collaboration between international pharmaceutical companies and Saudi Arabian healthcare providers has helped introduce advanced treatments. These partnerships ensure the availability of high-quality somatostatin analogs in the country, contributing to market growth.
   

Somatostatin Analogs Market Share

The top 6 companies in the market account for approximately 75% of the market share, including Pfizer, Novartis, Ipsen Pharma, Sun Pharmaceutical, Camurus AB, and Peptron Inc. These companies focus on developing new somatostatin analogs to address the growing burden of hormonal disorders such as neuroendocrine tumors (NETs) and acromegaly worldwide. Their strong research and development pipelines along with favorable regulatory environments and fast approval processes have helped introduce and adopt new somatostatin analogs. This regulatory support encourages major pharmaceutical companies in the market to launch their products, which helps market growth.
 

Additionally, companies such as Novartis, Pfizer, and Sun Pharmaceutical are increasing competition by offering affordable somatostatin analogs and expanding their product lines. For instance, in April 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (lutetium Lu 177 dotatate) for treating pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Moreover, companies are increasingly forming strategic partnerships, mergers, and acquisitions to strengthen their market presence, improve global distribution networks, and speed up the launch of new somatostatin analogs, which drives continued growth in the market.
 

Somatostatin Analogs Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

• Camurus
• Chiasma
• Crinetics Pharmaceuticals
• Dauntless Pharmaceuticals
• Debiopharm
• GlyTech
• Ipsen Pharma
• Novartis
• Peptron
• Pfizer
• Sun Pharmaceutical
• Teva Pharmaceuticals 
   
• Teva Pharmaceuticals offers somatostatin analogs such as Sandostatin, which is the first and only generic version of Sandostatin LAR Depot in the United States. With the launch of octreotide acetate for injectable suspension (the generic version of Sandostatin LAR Depot), Teva is giving patients a new option for the treatment of acromegaly.
   
• Camurus is a global player in somatostatin analogs. The company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Oclaiz (CAM2029) for the treatment of patients with acromegaly. The FDA's acceptance of the NDA submission for Oclaiz marks a milestone in the efforts to develop a new, effective treatment for patients with acromegaly. This treatment has the potential to reduce treatment burden and increase quality of life.
   

Somatostatin Analogs Industry News

• In November 2022, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT's PNT2002 and PNT2003 (a somatostatin receptor) product candidates. This helped the company expand its product range.
   
• In September 2021, Xeris Pharmaceuticals, Inc. announced that its stockholders approved the previously announced proposed acquisition of Strongbridge Biopharma plc. This acquisition aimed to broaden the treatment availability of Xeris Pharmaceuticals, including the addition of somatostatin analogs.
   
• In June 2020, Chiasma announced FDA approval of Mycapssa (octreotide) capsules, the first and only oral somatostatin analog. This product launch helped the company expand its product range.
   

The somatostatin analogs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Octreotide
• Lanreotide
• Pasireotide

Market, By Indication

• Neuroendocrine tumor (NET)
• Acromegaly
• Other indications

Market, By Route of Administration

• Oral
• Parenteral

Market, By End Use

• Hospitals
• Specialty clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE